CLINICAL_TRIALS
trial_result
· 2025-10-23
Clinical Trial Update: Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis [Phase 2]
Summary
The Phase 2 long-term safety and efficacy trial of tolebrutinib in relapsing multiple sclerosis has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Relapsing Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-10-23